ClinicalTrials.gg
CompletedNCT00608907Updated Jan 30, 2012Results posted

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

A Phase 1 interventional study of bortezomib and bortezomib, rifampicin in Multiple Myeloma and Non-Hodgkin's Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 9 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-30.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
83rd of 267
61 · median 41
Started
2007
with 14 others
Phase 1
41 of 271
1 open now
Registered
85th of 271
by date
Lead sponsor
6 of 271
Millennium Pharmaceuticals, Inc.

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 83rd largest by enrollment of the 267 interventional ones that give a count, is one of 15 that started in 2007, is one of 41 in phase 1, and was the 85th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib). Rifampicin will be used to assess the effect of a strong CYP3A4 inducer and dexamethasone to assess the effect of a relatively weak inducer. This study is also to evaluate the impact of CYP3A4 inducers on the pharmacodynamics (PD) of VELCADE and the safety profile of VELCADE.

03

Conditions studied

  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female of at least 18 years of age.
  • Has documented multiple myeloma or NHL following prior anti-neoplastic treatment.
  • Female patients must be post menopausal for at least 1 year (must not have had a natural menses for at least 12 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) before entry and throughout the study; have a negative serum β-HCG or a negative urine pregnancy test at screening. (an alternative to oral contraceptives should be used if the patient is randomized to Arm B with rifampicin).
  • Male patients must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study.
  • Must be able to swallow capsules/tablets whole (without chewing, crushing, or opening).
  • Agree to refrain from the use of any methylxanthine-containing products, including caffeine (e.g., chocolate bars or beverages, coffee, teas, or colas), on Day 11 of Cycles 2 and 3.
  • Agree to refrain from the use of any products containing nicotine, alcohol, quinine, grapefruit juice, or Seville oranges from 7 days before the first administration of VELCADE through completion of the 72-hour PK blood sample collection (post Day 11 VELCADE dose) in Cycle 3.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis or treatment of a other than multiple myeloma or NHL within 1 year of randomization, or who have previously been diagnosed with a malignancy other than multiple myeloma or NHL and have any radiographic or biochemical marker evidence of malignancy.
  • History of liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, psychiatric, or metabolic disturbances.
  • Known or suspected or intolerance to rifampicin and/or other antibiotics, , boron or mannitol.
  • Peripheral neuropathy or neuropathic pain Grade 2 or higher.
  • Preplanned surgery or procedures that would interfere with the conduct of the study or major surgery within 2 weeks before randomization.
  • History of disallowed therapies:

    • Prior treatment with VELCADE.
    • Any drugs or agents that inhibit (e.g., cimetidine, erythromycin, fluoxetine, ketoconazole, paroxetine) or induce (e.g., carbamazepine, glucocorticoids, phenobarbital, phenytoin, St. John's Wort) CYP2C19 or within 28 days before the first administration of VELCADE.
    • Any exposure to rifampicin or corticosteroids within 28 days of screening.
    • Have received an agent or used an investigational medical device within 28 days before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
  • Female patient who is pregnant or breastfeeding.
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    VELCADE

    Control arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle.

    Drug: bortezomib

  • Experimental
    VELCADE + rifampicin

    Treatment Arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3.

    Drug: bortezomib, rifampicin

  • Experimental
    VELCADE + dexamethasone

    Treatment arm, bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3.

    Drug: bortezomib, dexamethasone

Interventions

  • 1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle

    Also known as: VELCADE

  • Drugbortezomib, rifampicin

    Drug pages: Bortezomib · Rifampin

    bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3

    Also known as: bortezomib, rifampicin

  • Drugbortezomib, dexamethasone

    Drug pages: Bortezomib · Dexamethasone

    bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3

    Also known as: bortezomib, dexamethasone

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours

    Time frame: Cycle 3 day 14 (72 hours post last dose)

07

Results

Posted Jul 13, 2011

Participant flow

Participant flow — Overall Study
MilestoneVELCADEVELCADE + RifampicinVELCADE + Dexamethasone
Started301318
Completed181317
Not completed1201
Withdrew: Adverse event601
Withdrew: Death100
Withdrew: Withdrawal by subject400
Withdrew: Progressive disease100

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve (AUC) 0-72 Hours
Time frame:
Cycle 3 day 14 (72 hours post last dose)
Reported as:
Mean · ng*h/mL
Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours
ng*h/mLVELCADE + RifampicinVELCADE + DexamethasoneVELCADE
Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours123 ± 34.2170 ± 64.5215 ± 58.4

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VELCADE—14/30 (46.7%)28/30 (93.3%)
VELCADE + Rifampicin—5/13 (38.5%)13/13 (100%)
VELCADE + Dexamethasone—7/18 (38.9%)18/18 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventVELCADEVELCADE + RifampicinVELCADE + Dexamethasone
Renal FailureRenal and urinary disorders0/300/133/18
DiarrhoeaGastrointestinal disorders1/301/132/18
Upper Gastrointestinal HaemorrhageGastrointestinal disorders0/301/130/18
FatigueGeneral disorders0/301/130/18
PyrexiaGeneral disorders1/301/130/18
CellulitisInfections and infestations0/301/130/18
Device Related InfectionInfections and infestations0/301/131/18
DehydrationMetabolism and nutrition disorders0/301/131/18
DyspnoeaRespiratory, thoracic and mediastinal disorders2/301/130/18
Circulatory CollapseVascular disorders0/301/130/18
Most frequent other events
Showing 10 of 63
Most frequent other events
EventVELCADEVELCADE + RifampicinVELCADE + Dexamethasone
NeutropeniaBlood and lymphatic system disorders7/306/1310/18
Peripheral Sensory NeuropathyNervous system disorders7/306/1310/18
NauseaGastrointestinal disorders11/307/136/18
VomitingGastrointestinal disorders8/306/133/18
ThrombocytopeniaBlood and lymphatic system disorders8/305/138/18
Upper Respiratory Tract InfectionInfections and infestations7/302/137/18
Pain in ExtremityMusculoskeletal and connective tissue disorders6/305/134/18
DizzinessNervous system disorders5/305/132/18
CoughRespiratory, thoracic and mediastinal disorders6/305/131/18
HeadacheNervous system disorders11/303/134/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)VELCADEVELCADE + RifampicinVELCADE + DexamethasoneTotal
<=18 years0000
Between 18 and 65 years148830
>=65 years1651031
Age Continuous
Age Continuous(years)VELCADEVELCADE + RifampicinVELCADE + DexamethasoneTotal
Mean64.7 ± 10.8660.2 ± 9.9762.3 ± 11.7263.0 ± 10.91
Sex: Female, Male
Sex: Female, Male(Participants)VELCADEVELCADE + RifampicinVELCADE + DexamethasoneTotal
Female157931
Male156930
08

Study locations

9 sites
  • Hematology Institute - Davidoff Center - Rabin Medical Center
    Petach Tikva, 49100, Israel
  • Divisione di Ematologia - Ospedale S Eugenio - P. le dell'Umanesimo
    Rome, 10001, Italy
  • Medical Academy - Dept of Hematology and Transplantology
    Gdansk, 80-952, Poland
  • Klinika Nowotworow Ukladu - Chlonnego - Centrum Onkologii - Instytut
    Warszawa, 02-781, Poland
  • Hematological Oncology
    Parow, Cape Town, South Africa
  • Department of Hematology - University of the Free State
    Bloemfontein, 9300, South Africa
  • Department of Medical Oncology - Ward 51 - Pretoria Academic Hospital
    Pretoria, 0001, South Africa
  • Plymouth Hospitals NHS Trust - Derriford Hospital
    Derriford, Plymouth PL68DH, United Kingdom
  • Hematology Department Combined Laboratories - Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Mar 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2008
First posted
Feb 6, 2008
Start
Sep 2007
Primary completionActual
Mar 2010
CompletionActual
Apr 2010
Results first posted
Jul 13, 2011
Last update
Jan 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00608907
Responsible party
Sponsor
First posted
Feb 6, 2008
Start date
Sep 2007
Primary completion
Mar 2010
Completion
Apr 2010
Results posted
Jul 13, 2011
Last update
Jan 30, 2012

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Rifampin · Dexamethasone

Start the discussion